Adtech Pharma has developed a novel formulation of a synthetic cannabinoid therapeutic specifically targeting glaucoma, utilizing a breakthrough mechanism of action to enhance intraocular pressure management. This treatment is designed for patients who do not respond to existing therapies, addressing a significant global health issue that can lead to blindness if untreated.
Funding
Funding not disclosed
Founders
Product
Problem
Existing glaucoma treatments are not effective for all patients, and a significant portion of individuals do not respond adequately to current therapies. Untreated or poorly managed glaucoma can lead to irreversible vision loss and blindness.
Solution
Adtech Pharma is developing a novel synthetic cannabinoid formulation designed to effectively manage intraocular pressure in glaucoma patients who are non-responsive to existing treatments. This therapeutic leverages a new mechanism of action to address the underlying causes of elevated intraocular pressure. The treatment aims to provide a scientifically proven, safe, and effective alternative for patients facing the risk of blindness due to poorly managed glaucoma. Adtech Pharma's platform technology may also be applicable to additional indications beyond glaucoma.
Target Audience
The primary target audience includes glaucoma patients who have not found relief with existing treatments, as well as ophthalmologists and other eye care professionals seeking alternative therapeutic options.
Features
- Novel synthetic cannabinoid formulation
- New mechanism of action for intraocular pressure management
- Designed for patients non-responsive to current glaucoma therapies
- Potential for additional indications beyond glaucoma
- Patent protection available through the 2040s
- US 505(b)(2) regulatory approval pathway